Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pluri Inc. Declaration of Voting Results & Voting Rights Announcements 2014

May 22, 2014

6990_rns_2014-05-22_9480687b-5395-4485-ba25-0f3b3de97999.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in viewer

Opens in your device viewer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report: May 22, 2014

PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant as Specified in Its Charter)

Nevada (State or Other Jurisdiction of Incorporation)

001-31392 (Commission File Number)

98-0351734 (IRS Employer Identification No.)

MATAM Advanced Technology Park Building No. 5 Haifa, Israel (Address of Principal Executive Offices)

31905 (Zip Code)

011 972 74 710 7171 (Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.07. Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the "Company"), held its annual meeting of stockholders on May 22, 2014. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name For Against Abstain Broker Non-Votes
Zami Aberman 15,225,574 3,653,462 26,907 15,245,366
Israel Ben-Yoram 18,611,618 130,728 163,597 15,245,366
Isaac Braun 18,667,408 72,388 166,147 15,245,366
Mark Germain 18,604,030 138,105 163,808 15,245,366
Moria Kwiat 18,602,861 143,824 159,258 15,245,366
Hava Meretzki 18,635,058 136,101 134,784 15,245,366
Nachum Rosman 18,631,094 109,942 164,907 15,245,366
Doron Shorrer 16,241,054 2,505,521 159,368 15,245,366

Proposal No. 2 — Amendment to the Company's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock

For Against Abstain Broker Non-Votes
30,674,537 2,725,415 177,798 573,559

Proposal No. 3 — Ratification of the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as independent registered public accounting firm of the Company for the fiscal year ending June 30, 2014

For Against Abstain Broker Non-Votes
32,771,414 393,910 184,128 N/A

The results reported above are final voting results.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

Date: May 22, 2014

By: /s/ Boaz Gur-Lavie Name: Boaz Gur-Lavie Title: Chief Financial Officer and Secretary